Navigation Links
Filing Yaz Class Action Lawsuits Before They Expire
Date:7/18/2012

HOUSTON, July 18, 2012 /PRNewswire/ -- The attorneys at Pulaski & Middleman, LLC are actively representing women affected by the adverse side effects of the birth control drugs Yaz and Yasmin and the maker of the drugs, Bayer Pharmaceuticals. Medical malpractice lawyers are committed to protecting the legal rights of women who have been misinformed of the risks of taking these drugs.  The cutoff date for filing has not yet been determined, but the current Class Action Settlement will likely close within a year or less. Since the timeframe is unclear, it is highly recommended that women take action and file their suits now.

Bayer Pharmaceuticals recently indicated which types of cases it would agree to settle as well as what the average amount would be. More than 10,000 individuals have filed a Yaz lawsuit. The formal class action lawsuit is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation.

The most common lawsuits that have been filed are by women have suffered stroke, Deep Vein Thrombosis (DVP) or Pulmonary Embolism after taking Yaz. Recent studies have linked drospirenone, the chemical present in the birth control drugs, to blood clots that can cause these conditions to occur. The FDA recently released a study, which followed more than 825,000 women taking oral contraceptives and found that women taking Yaz face up to a 74% increased risk of developing blood clots, DVT and pulmonary embolism.

The law office of Pulaski & Middleman, LLC urges women who have experienced these life-threatening injuries to contact an experienced personal injury lawyer and investigate your rights now. The window of time to claim your injury is small as it took Bayer Pharmaceuticals 4 years to open up the settlements.

Contact the experienced Yaz attorneys at Pulaski & Middleman, LLC today if you or a loved one has experienced the harmful effects of the birth control drug. Contact toll free at 1-800-BAD-DRUG.


'/>"/>
SOURCE Pulaski & Middleman, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
2. Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
3. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
4. Attorneys for Class of Female VPs and SVPs Employed by PR Giant MSLGroup Clarify Companys Inaccurate Description of Federal Courts Recent Certification Ruling
5. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
6. Sanford Wittels & Heisler Files $100 Million Gender Discrimination Class Action In Southern District Of New York
7. Boston Scientific Completes Patient Enrollment in PREVAIL Study for First-in-Class WATCHMAN Device
8. Frost & Sullivan: Launch of New Classes of Oral Antidiabetic Drugs by 2014 will Uplift Prospects for the European Diabetes Therapeutics Market
9. Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
10. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
11. eCardios CEO to Speak During "Act at the Speed of Opportunity" Event Presented by Comcast Business Class and Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... -- A key trend that will boost ... new treatments. Cardax, a development stage life sciences company, ... is expected to fulfil large unmet medical needs in ... to develop new treatments for osteoarthritis. One such study ... osteoarthritis are being investigated, and early trials of stem-cell ...
(Date:5/26/2016)... May 26, 2016 Since its ... into an essential life science tool for conducting genetic ... BCC Research reveals in its new report that the ... phase, one powered by a range of new applications ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient dringenden ... Brustkrebs   QIAGEN N.V. (NASDAQ: ... heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis ... für die Onkologie eingegangen zu sein. Ein erstes ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the Federal ... an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center at ... Committee (FOMC) dot charts are of interest to the press for their noise potential,” ...
(Date:5/26/2016)... Missouri (PRWEB) , ... May 26, 2016 , ... ... quality and clinical outcomes, hosted members and suppliers for its inaugural Member Conference ... focus on their mission of elevating the operational health of America’s healthcare providers. ...
(Date:5/26/2016)... ... , ... The Woodlands at John Knox Village , Florida’s first Life ... living and healing, celebrated its grand opening, today. The Woodlands at John Knox Village ... Empowered Staff. , “This is an incredibly fulfilling time for John Knox Village as ...
(Date:5/26/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... global clinical supply services, today announced two key appointments and the opening of ... strategic growth plans in the Asia Pacific region. , Howard Kim has joined ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks the unofficial ... is sharing tips to make sure your family and vehicle are ready to ... Council, there may be 439 deaths and an additional 50,500 serious injuries from motor ...
Breaking Medicine News(10 mins):